MedTrace Logo

A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin

NCT00892008 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2278

Last updated 2021-01-25

Study results available
· View outcomes & findings →

Summary

This study is being conducted as a regulatory requirement post initial marketing authorization. This is primarily a safety study. This was an open label study and patients were enrolled once the decision to prescribe the medication was made by the Investigator.

Conditions

  • Neuropathic Pain

Interventions

DRUG

Pregabalin

Pregabalin 75-150 mg BID for at least 2 weeks.

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-08-31
Completion
2008-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00892008 on ClinicalTrials.gov